UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations in the US each year, GSK said.

A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

Antibiotic resistance is a major threat to human health. But experts say there are steps people can take to reduce the risk.

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite ...

Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...

GSK's Blujepa (gepotidacin) becomes the first in a new class of oral antibiotics to treat uncomplicated UTIs (also known as uUTIs) in almost 30 years, taking aim at infection-causing bacteria ...

GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...

The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the treatment of uncomplicated urinary tract infections (UTIs) in women aged ...